Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23675243 | 1.00 | HPGD (0.58) | HPGDADORA2ADDR1MGLLCYP3A4 | |
| SCHEMBL28887329 | 0.96 | HPGD (0.55) | HPGDADORA2ADDR1MGLLCYP3A4 | |
| SCHEMBL23680590 | 0.89 | HPGD (0.52) | HPGDADORA2ADDR1MGLLCYP3A4 | |
| SCHEMBL23675168 | 0.89 | HPGD (0.48) | HPGDADORA2ADDR1MGLL | |
| SCHEMBL29564765 | 0.89 | HPGD (0.48) | HPGDADORA2ADDR1MGLL | |
| SCHEMBL23680822 | 0.88 | HPGD (0.74) | HPGDADORA2AMGLLHRH3 | |
| SCHEMBL23680742 | 0.88 | HPGD (0.59) | HPGDADORA2ADDR1MGLLHRH3 | |
| SCHEMBL23675344 | 0.85 | HPGD (0.61) | HPGDDDR1MGLLCYP3A4ALDH1A1 | |
| SCHEMBL24942913 | 0.85 | HPGD (0.61) | HPGDDDR1MGLLCYP3A4USP2 | |
| SCHEMBL24942620 | 0.85 | HPGD (0.51) | HPGDADORA2ADDR1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335043-B | PGDH inhibitors and methods of making and using the same | 迈欧伏特治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-118338902-A | Pyrrolo [2,3-b ] pyridine PGDH inhibitors and methods of making and using the same | 埃皮里姆生物股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4376841-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023009642-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |